🔎 Trials Near Me

Akèy › Miasteni grav › Ohio

Etid klinik pou Miasteni grav nan Ohio

13 etid pou Miasteni grav ap chèche patisipan nan sit nan Ohio.

Vil nan Ohio

Tèks ofisyèl etid la (Anglè)

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  • Mg0038 10103, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07463521

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

  • University of Cincinnati Medical Center - Goodman St, Cincinnati
  • Ohio State Martha Morehouse Outpatient Care, Columbus
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07294170

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  • Mg0039 10103, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07465289

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

  • University of Cincinnati Medical Center - Goodman St, Cincinnati
  • Ohio State Martha Morehouse Outpatient Care, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07284420

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  • Miami Valley Hospital South, Centerville
  • University of Cincinnati, Cincinnati
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06463587

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

  • TG Therapeutics Investigational Trial Site, Cleveland
  • TG Therapeutics Investigational Trial Site, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06680037

Zilucoplan for Severe gMG Exacerbations

  • The Ohio State University, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07215949

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

  • The Ohio State University, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06414954

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

  • Site Number - 1038, Cincinnati
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT07039916

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  • Cleveland Clinic, Cleveland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT04951622

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

  • University of Cincinnati Health Physicians - Clifton, Cincinnati
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT06456580

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

  • Ohio State University, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT06626919

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

  • Clinical Trial Site, Dayton
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 18, 2026 · NCT04202341

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.